enVVeno Medical (NVNO)
(Delayed Data from NSDQ)
$3.37 USD
+0.06 (1.81%)
Updated Oct 31, 2024 04:00 PM ET
After-Market: $3.39 +0.02 (0.59%) 6:58 PM ET
3-Hold of 5 3
D Value B Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NVNO 3.37 +0.06(1.81%)
Will NVNO be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for NVNO based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for NVNO
enVVeno Medical reports Q3 EPS (35c) vs. (45c) last year
enVVeno Medical expects capital to fund company through several milestones
enVVeno Medical expects capital to fund company through several milestones
enVVeno Medical reports Q3 EPS (35c) vs. (45c) last year
enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year